CM Management’s Pacira BioSciences PCRX Stock Holding History

CM Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$602K	–	83
2021 Q4	$602K	Buy	+10,000	New	+$551K	0.45%	66

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CM Management's PCRX Position: Q1 2022 in Review

CM Management sold out of Pacira BioSciences (PCRX) in Q1 2022, closing a stake of 10,000 shares — an estimated $602K sold.

CM Management first reported a position in PCRX in Q4 2021 and held it in 1 quarter. The position peaked at $602K in Q4 2021. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

CM Management reported no remaining Pacira BioSciences position as of Q1 2022 after selling out during the quarter.
CM Management sold 10,000 Pacira BioSciences shares in Q1 2022, an estimated $602K.
CM Management first reported a position in Pacira BioSciences in Q4 2021 and held it in 1 quarter.
CM Management's Pacira BioSciences position peaked at $602K in Q4 2021.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on CM Management's 13F filing for Q1 2022, filed 9 May 2022.